 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || 212Pb-VMT-?-NET / Perspective Therap
New P1 trial: A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors (clinicaltrials.gov) - Nov 28, 2023
P1, N=24, Recruiting, Sponsor: David Bushnell
- ||| Enrollment open, Metastases: 212-Pb-VMT: Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors (clinicaltrials.gov) - Nov 8, 2023
P1/2, N=52, Recruiting, Sponsor: Viewpoint Molecular Targeting
Not yet recruiting --> Recruiting
- || Trial initiation date, Metastases: 212-Pb-VMT: Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors (clinicaltrials.gov) - May 9, 2023
P1/2, N=52, Not yet recruiting, Sponsor: Viewpoint Molecular Targeting
Not yet recruiting --> Recruiting Initiation date: Mar 2023 --> Jul 2023
- |||| New P1/2 trial, Metastases: 212-Pb-VMT: Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors (clinicaltrials.gov) - Dec 5, 2022
P1/2, N=52, Not yet recruiting, Sponsor: Viewpoint Molecular Targeting